About This Webinar
Ensuring optimal immunizations rates of long-acting monoclonal antibody (mAb) is a critical clinical and public health intervention to prevent Respiratory Syncytial Virus (RSV) disease among pediatric patients. The Advisory Committee on Immunization Practices recommends nirsevimab for infants aged <8 months born during or entering their first RSV season and for infants and children aged 8–19 months who are at increased risk of severe RSV disease entering their second RSV season. RSV mAb is recommended for healthy, term newborns in their first week of life, either during the birth hospitalization or in a follow-up office visit.
However, according to the Centers for Disease Control and Prevention (CDC), the birth hospital is the preferred site of immunization to overcome concerns with delayed or forgone follow-up care. This webinar will explore how payers can implement coverage and payment solutions to support administration of RSV mAb prior to discharge from the birth hospital.
RSV is a common infection and risk is highest during the first few months of life. Healthy, term newborns now have access to immunization, but there are limited touch points for administration along the continuum of care. While RSV mAb may be administered in the hospital- or office-based settings, not all families attend a follow-up visit within the first week of life. Shifting immunization upstream to the hospital will enhance immunization rates across pediatric populations, enhancing clinical outcomes and avoiding downstream utilization.
Attendees Will Learn About
- The clinical and public health importance of timely RSV mAb administration
- The cost-effectiveness of RSV immunization
- How the traditional newborn reimbursement framework disincentivizes administration during the birth hospitalization
- Coverage and payment solutions to support inpatient immunization
- Specific contract language to facilitate separate payment with hospitals
